Canagliflozin Intermediate；2-(4-fluorophenyl)-5-[(5-bromo-2-methylphenyl)methyl]thiophene; 2-(2-methyl-5-bromobenzyl)-5-(4-fluorophenyl)thiophene; 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene
CAS: 1030825-20-7
Chemical Formula: C₁₈H₁₄BrFS
Molecular Weight: 361.27
Availability: R&D; Commercialization
⬤ CAS No.1030825-20-7
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | 2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene |
| CAS.No | 1030825-20-7 |
| Molecular Formula | C₁₈H₁₄BrFS |
| Molecular Weight | 361.27 |
| Related Categories | Canagliflozin intermediates |
| Appearance | Light yellow to white powder |
| Density | 1.388 |
| Melting Point | 103 °C |
| Boiling Point | 438.3±40.0 °C(Predicted) |
| Storage Conditions | Keep in dark place,Sealed in dry,Room Temperature |
| Solubility | Soluble in DMSO (slightly warmed), hexane (slightly warmed) |
| Form | solid |
| Chemical properties | The compound has a thiophene ring structure, as well as brominated and fluorinated substituents, which give it unique reactivity in organic synthesis. |
| Application | Canagliflozin intermediates, a raw material for the treatment of type 2 diabetes in adult patients. |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
